ClinicalTrials.gg

Program

emavusertib

Its studies are mostly in Hematologic Neoplasms · Leukemia, Lymphocytic, Chronic, B-Cell · Leukemia, Myeloid, Acute, led by Curis.

Furthest: phase 2, since Oct 17, 20173 company-led studies, 2 open or runningNext primary completion: Jul 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Curis32 open or runningphase 2since Oct 17, 2017Oct 17, 2017Jul 2027phase 2 · NCT03328078

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 17, 2017First study: phase 2 study in Hematologic NeoplasmsFirst studyNCT03328078 · 152 planned · United States, Czechia, France and more
  2. Feb 10, 2020Phase 2 study in Leukemia, Myeloid, AcuteNCT04278768 · 366 enrolled · United States, Czechia, France and more
  3. Nov 26, 2025Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07271667 · 108 planned · United States, Italy, Spain

Ahead

  1. Jul 2027Primary completion: phase 2 study in Hematologic NeoplasmsNCT03328078
  2. Nov 2027Primary completion: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07271667

TargetBeta

IRAK4 →read by rule
“An orally bioavailable, reversible inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), ”NCIt, by rule

Other programs on IRAK4

ProgramCompanyFurthest phaseStudies
IRAK4 Inhibitor AZD2962ruleAstraZenecaphase 11
ARD-885ruleartivila-shenzhen-innovation-center-ltdphase 11
HPB-092rulehangzhou-polymed-biopharmaceuticals-incphase 11
SAR447971Sanofiphase 11

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07271667Leukemia, Lymphocytic, Chronic, B-Cell · United States, Italy, Spain2RecruitingNov 2027108
NCT04278768Leukemia, Myeloid, Acute · United States, Czechia, France and more2SuspendedApr 1, 2026366
NCT03328078Hematologic Neoplasms · United States, Czechia, France and more2RecruitingJul 2027152

How it is read

Names in the registry

  • “Emavusertib”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.